

# J PÃ©rez Fidalgo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8889217/publications.pdf>

Version: 2024-02-01

89  
papers

3,809  
citations

186265

28  
h-index

128289

60  
g-index

95  
all docs

95  
docs citations

95  
times ranked

7414  
citing authors

#	ARTICLE	IF	CITATIONS
1	Emergence of Constitutively Active Estrogen Receptor- $\beta$ Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1757-1767.	7.0	529
2	Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. <i>Cancer Treatment Reviews</i> , 2012, 38, 698-707.	7.7	466
3	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	16.2	449
4	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2251-2259.	1.6	240
5	Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 479-484.	2.5	154
6	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 60-67.	7.7	150
7	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 102-113.	9.4	136
8	Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4764-4774.	7.0	132
9	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1382-1389.	4.1	104
10	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology</i> , 2018, 19, 812-824.	10.7	98
11	A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 2050-2059.	7.0	96
12	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	7.0	76
13	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	1.6	69
14	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 507-515.	2.5	60
15	BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a <i>PIK3CA</i> mutant sub-population. <i>Annals of Oncology</i> , 2019, 30, 774-780.	1.2	57
16	MicroRNA profile in very young women with breast cancer. <i>BMC Cancer</i> , 2014, 14, 529.	2.6	56
17	Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 245-251.	2.5	53
18	Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?. <i>Breast</i> , 2011, 20, 548-554.	2.2	53

#	ARTICLE	IF	CITATIONS
19	Pulmonary Fibrosis Induced by Cyclophosphamide. <i>Annals of Pharmacotherapy</i> , 2001, 35, 894-897.	1.9	52
20	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i> -Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	1.6	43
21	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	4.4	41
22	A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. <i>Clinical Epigenetics</i> , 2019, 11, 33.	4.1	39
23	Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: A prospective study. <i>Palliative Medicine</i> , 2014, 28, 326-334.	3.1	37
24	Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 285-298.	2.3	37
25	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	4.4	37
26	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targets—a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1712-1712.	1.7	36
27	Deregulation of <i>ARID1A</i> , <i>CDH1</i> , <i>cMET</i> and <i>PIK3CA</i> and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015, 6, 26935-26945.	1.8	35
28	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , 2009, 11, 787-798.	2.4	33
29	Analysis of Clinical Prognostic Factors for Survival and Time to Progression in Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2003, 2, 231-234.	2.3	29
30	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 2517-2529.	7.0	26
31	NOTCH signalling in ovarian cancer angiogenesis. <i>Annals of Translational Medicine</i> , 2020, 8, 1705-1705.	1.7	24
32	SEOM clinical guideline in ovarian cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 961-968.	2.4	22
33	Clinical implications of routine genomic mutation sequencing in <i>PIK3CA</i> / <i>AKT1</i> and <i>KRAS</i> / <i>NRAS</i> / <i>BRAF</i> in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 69-77.	2.5	20
34	Parotid gland metastasis of a breast cancer. <i>Clinical and Translational Oncology</i> , 2007, 9, 264-265.	2.4	19
35	Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 26.	5.0	19
36	Candidate Gene and Genome-Wide Association Studies for Circulating Leptin Levels Reveal Population and Sex-Specific Associations in High Cardiovascular Risk Mediterranean Subjects. <i>Nutrients</i> , 2019, 11, 2751.	4.1	16

#	ARTICLE	IF	CITATIONS
37	Abstract C252: A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies.. <i>Molecular Cancer Therapeutics</i> , 2013, 12, C252-C252.	4.1	16
38	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	5.0	15
39	Aurora kinases in ovarian cancer. <i>ESMO Open</i> , 2020, 5, e000718.	4.5	15
40	A phase III trial of alpelisib+trastuzumab ±fulvestrant versus trastuzumab+ chemotherapy in HER2+ PIK3CA-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349.	2.4	15
41	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	6.4	14
42	Zoledronic acid in the treatment of metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2014, 25, 1-7.	1.4	13
43	First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3022-3022.	1.6	13
44	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 669-669.	1.6	11
45	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016, 7, 22543-22555.	1.8	11
46	Abstract CT-02: A phase I, open label, dose escalation study of oral mammalian target of rapamycin inhibitor INK128 administered by intermittent dosing regimens in patients with advanced malignancies. <i>Cancer Research</i> , 2012, 72, CT-02-CT-02.	0.9	10
47	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0130543.	2.5	9
48	Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer. <i>ESMO Open</i> , 2021, 6, 100300.	4.5	9
49	Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain). <i>Clinical and Translational Oncology</i> , 2008, 10, 745-752.	2.4	7
50	An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer. <i>Breast</i> , 2013, 22, 974-979.	2.2	7
51	Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 814-822.	2.4	7
52	Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 1053.	2.0	6
53	GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. <i>Future Science OA</i> , 2019, 5, FSO370.	1.9	6
54	A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2500-2500.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2018, 20, 274-285.	2.4	5
56	Paclitaxel-Induced Epidermal Alterations: An In Vitro Preclinical Assessment in Primary Keratinocytes and in a 3D Epidermis Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1142.	4.1	5
57	Associations between Taste Perception Profiles and Empirically Derived Dietary Patterns: An Exploratory Analysis among Older Adults with Metabolic Syndrome. <i>Nutrients</i> , 2022, 14, 142.	4.1	5
58	Primitive neuroectodermal kidney tumor. <i>Medical and Pediatric Oncology</i> , 2002, 38, 145-145.	1.0	4
59	Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer. <i>Clinical and Translational Oncology</i> , 2005, 7, 23-28.	2.4	4
60	Chronological Age Interacts with the Circadian Melatonin Receptor 1B Gene Variation, Determining Fasting Glucose Concentrations in Mediterranean Populations. Additional Analyses on Type-2 Diabetes Risk. <i>Nutrients</i> , 2020, 12, 3323.	4.1	4
61	Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 530-530.	1.6	4
62	Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?. <i>Gynecologic Oncology</i> , 2022, 164, 406-414.	1.4	4
63	Primary carcinoid tumour of the pancreas. <i>Clinical and Translational Oncology</i> , 2006, 8, 54-56.	2.4	3
64	The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS3637-TPS3637.	1.6	3
65	A phase II clinical trial to analyze olaparib response in patients with <i>BRCA1</i> and/or <i>BRCA</i>2 promoter methylation with advanced breast cancer (GEICAM/2015-06 COMETA-Breast study).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1114-TPS1114.	1.6	3
66	High risk Ewing's sarcomas. Effectiveness and toxicity of a regimen designed for children and used in adults. <i>Clinical and Translational Oncology</i> , 2004, 6, 165-169.	2.4	2
67	Subcutaneous trastuzumab: drug development and current position. <i>Clinical and Translational Oncology</i> , 2014, 16, 859-864.	2.4	2
68	Abstract CT331: "BEECH", a phase I/II study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with advanced or metastatic breast cancer: results from the dose-finding study, including quantitative assessment of circulating tumor DNA as a s. , 2015, , .		2
69	Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 2555-2555.	1.6	2
70	Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2606-2606.	1.6	2
71	Non-Hodgkin's Lymphoma in Older People: Age Is Not Always an Adverse Prognostic Factor. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 1911-1912.	2.6	1
72	High grade gliomas. Multidisciplinary treatment with radiotherapy and concurrent carmustine after surgery. <i>Clinical and Translational Oncology</i> , 2004, 6, 207-211.	2.4	1

#	ARTICLE	IF	CITATIONS
73	Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?. <i>European Journal of Surgical Oncology</i> , 2012, 38, 643-644.	1.0	1
74	Reply to â€˜Comment on: management of chemotherapy extravasation: ESMOâ€™EONS clinical practice guidelines'. <i>Annals of Oncology</i> , 2013, 24, 1129-1130.	1.2	1
75	DNA methylation signature to identify treatment response in triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 1079-1079.	1.6	1
76	DNA methylation as an epigenetic signature predictive of response to neoadjuvant treatment in TNBC patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12658-e12658.	1.6	1
77	Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+ breast cancer cells with de novo resistance to trastuzumab.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11592-e11592.	1.6	1
78	Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network. <i>Cancers</i> , 2022, 14, 1965.	3.7	1
79	Breast Cancer Stem Cells. , 2014, , 107-126.		0
80	In the literature: June 2018. <i>ESMO Open</i> , 2018, 3, e000401.	4.5	0
81	Switching to aromatase inhibitor (AI) after tamoxifen in premenopausal patients with chemotherapy-induced amenorrhea (CIA) after early breast cancer treatment.. <i>Journal of Clinical Oncology</i> , 2011, 29, e11099-e11099.	1.6	0
82	Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14589-e14589.	1.6	0
83	Retrospective analysis of the use of GCSF and its impact on dose-response effect for anthracycline plus taxane-based schedules in early breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11523-e11523.	1.6	0
84	Impact of the delivery of adjuvant anthracycline-based nontaxane chemotherapy schedules on the outcome of breast cancer patients: Results from a retrospective database analysis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1074-1074.	1.6	0
85	Nova era en el combat contra el cÃncer: evoluciÃ³ i cÃncer: progrÃ©s i tractament de tumors. MÃ©tode Revista De DifusiÃ³ De La InvestigaciÃ³ De La Universitat De ValÃ©ncia, 2013, .	0.0	0
86	Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2548-2548.	1.6	0
87	A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trialâ€™A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5610-TPS5610.	1.6	0
88	Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3089-3089.	1.6	0
89	Abstract P6-03-05: AXL-HER2 dimer as mechanism of anti-HER2 acquired resistance in HER2 amplified breast cancer models: A new step towards precision medicine. , 2020, , .		0